Neoadjuvant immunotherapy could considerably improve long-term outcomes and quality of life for patients with desmoplastic melanoma, according to prospective study results.Nearly three-quarters of ...

Draft guidance from NICE recommends durvalumab before and after surgery for muscle-invasive bladder cancer following phase 3 trial survival data.

Neoadjuvant immunotherapy plus chemotherapy shows a 35% pathological complete response rate and 49% major pathological response rate in LS-SCLC. Most patients achieved R0 surgical resection, with a 44 ...

The results of the phase 3 ATOMIC trial fired another volley in the ongoing debate over adjuvant vs neoadjuvant immunotherapy for patients with locally advanced colon cancer. But experts are divided ...

Please provide your email address to receive an email when new articles are posted on . Most patients achieved complete response with dostarlimab alone. Further research is needed given the ...

Neoadjuvant pembrolizumab achieved a 71% pCR rate in desmoplastic melanoma, surpassing expectations for neoadjuvant anti–PD-1 ...

Researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy have ...

Both survival and safety outcomes after neoadjuvant immunotherapy appear favorable for appropriate patients with muscle-invasive bladder cancer undergoing chemoradiation. Neoadjuvant immunotherapy in ...

Major pathological response to neoadjuvant immune-related therapy and influence on long-term survival in patients with locally advanced oral squamous cell carcinoma. This is an ASCO Meeting Abstract ...

Failure patterns and the value of postoperative adjuvant radiotherapy in esophageal squamous cell carcinoma patients treated with neoadjuvant immunotherapy combined with chemotherapy. This is an ASCO ...

Investigators tested a new neoadjuvant immunotherapy to fight prostate cancer using a virus-mimicking drug to activate the immune system.

The trial evaluates survival outcomes for recurrent head and neck squamous cell carcinoma post-radiation therapy, comparing surgery alone to neoadjuvant chemotherapy with or without immunotherapy.